Low dose IL-2 therapy increased Tregs in mouse models, and this led to human trials of low dose IL-2; however, while this boosted human Treg numbers, it did not affect T1D outcome in initial trials (72). The gene discussed is IL2; the disease is type 1 diabetes mellitus.